Molecular pathogenesis of astrocytic tumours
Koichi Ichimura1, Hiroko Ohgaki, Paul Kleihues
1Department of Pathology, University of Cambridge, Cambridge, UK.
Journal of Neuro-Oncology
|January 28, 2005
Summary
Understanding adult astrocytic tumors is advancing, but molecular details for targeted treatments remain elusive. This review covers classification and genetic data for better diagnosis and prognosis.
Area of Science:
- Neuro-oncology
- Molecular pathology
- Cancer genetics
Background:
- Significant advancements in understanding diffuse adult astrocytic tumors' molecular pathogenesis have occurred.
- Knowledge gaps persist regarding molecular processes in various astrocytic tumors, hindering targeted therapies.
- Current clinical practice relies heavily on histology, with limited integration of molecular data.
Purpose of the Study:
- To summarize histological classification criteria for all astrocytic tumors.
- To review available genetic data for astrocytic tumors.
- To highlight diagnostic challenges and the future role of molecular data in patient care.
Main Methods:
- Review of current World Health Organization (WHO) classification of astrocytic tumors.
- Compilation and summary of existing genetic data for astrocytic tumors.
- Analysis of diagnostic challenges in astrocytic tumor pathology.
Main Results:
- The WHO classification includes six main entities of astrocytic tumors, some with subgroups.
- Diagnostic difficulties in astrocytic tumors are common.
- Molecular findings, while not yet standard clinical practice, are crucial for future treatment and prognosis.
Conclusions:
- Histological classification remains the cornerstone for astrocytic tumors.
- Molecular data is increasingly vital for accurate diagnosis, prognosis, and personalized treatment selection.
- The integration of molecular insights into clinical practice is imminent for improved patient outcomes.
